CliffBio
small molecule

OSMOVIST 240

IOTROLAN

Loss of exclusivity—loss of exclusivity
CompanyBayer Healthcare →See this company's full patent-cliff portfolio

Drug detail

Brand nameOSMOVIST 240
Active ingredientIOTROLAN
Strength51.3%
Dosage formINJECTABLE
RouteINTRATHECAL
ModalitySmall molecule
FDA approvalDecember 1989
Marketing statusDISCN

More from Bayer Healthcare

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.